Ipilimumab for Oral Squamous Cell Carcinoma

Signs of oral cancer involve the gums, the tongue and the cheeks. It is important to know what the signs are because they may be the first signs of cancer and should be managed accordingly by the health care professionals.

Even though, many patients who are curable after primary IMRT with or without CCRT have a long-term disease-free survival, the survival was still not satisfactory.

This article outlines some common treatments for oral SCC, and suggests that treatment can not be simplified to a single modality. The best therapy needs to be tailored to the individual patient.

There is no consistent link between oral SCC and either tobacco or beer. No single environmental factor can be clearly identified, but the risk of developing oral SCC is higher in patients who have a sibling who is affected. Although the oral SCCs are often found in patients who drink alcohol, this is not true in patients from non-alcoholic families who have SCCs. The risk for developing oral SCC may also be an indicator of other underlying familial cancer syndromes, such as Li-Fraumeni syndrome.

The risk of developing oral SCC increases progressively with age, regardless of tobacco consumption. A previous history of non-alcoholic and alcoholic OJ and being a male are risk factors of oral SCC. Patients with oral and oropharyngeal SCCs require meticulous medical surveillance.

The incidence of oral squamous cell carcinoma is higher than most other oral and pharyngeal cancer in the U.S. and is rising faster than many other forms of cancer. This is a global challenge to tackle in a global health arena.

There are many conditions that ipilimumab has been reported for, all [for example, autoimmune disorders and cancers] can have a variety of side effects, and in general, the side effects [at least what patients experience] may change depending on if it is used in clinic or if it is part of a trial. The side effects of ipilimumab vary based on the disease it treats. There is no way to tell where you will get side effects before taking the drug. For example, if you plan to use ipilimumab to treat an [autoimmune disorder] you may have some side effects while you are taking it. Once you start you may need to take the drug for your entire life.

The occurrence of oral carcinoma in multiple members of a family would be an important finding in the differential diagnosis of oral cancer. The authors found no evidence that oral carcinoma runs in families.

Although there have been many important discoveries in the treatment of oral squamous cell carcinoma, it is still extremely difficult to get these drugs into society.

Patients receiving ipilimumab experienced a substantial fraction (18-20%) of common side effects, comparable to those seen in clinical studies of ipilimumab but not matched cohorts receiving chemotherapy for cancer or immune checkpoint inhibitor with chemotherapy previously. This should be considered in the evaluation of the benefits and limitations of ipilimumab therapy in individual patients. summary: Data from a recent study lists common side effects of ipilimumab therapy. Clinical trials with ipilimumab in patients who received prior chemotherapy will be helpful for determining the most common side effects of ipilimumab.

The use of molecular probes like immunohistochemistry or gene profiling in the evaluation of the biopsy is probably more likely to be a marker of the disease process rather than a marker of a particular disease state and should also be included in the clinical practice of oropharyngeal carcinoma management. As molecular markers improve in their sensitivity, specificity, and technical ease of use, more stringent clinical validation and incorporation of such biomarkers into prospective studies will be needed for better management of oro-pharyngeal carcinoma.